This week, four Pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Johnson & Johnson (NYSE:JNJ) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, and Equity, JNJ also gets A’s. At present, the stock has a dividend yield of 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
Bristol-Myers Squibb (NYSE:BMY) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. Shares of BMY have increased 16.7% over the past month, better than the 4.5% increase the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of BMY stock.
This week, Watson Pharmaceuticals (NYSE:WPI) pushes up from a B to an A rating. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
The rating of Repros Therapeutics (NASDAQ:RPRX) moves up this week, rising from a B to an A. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.